Skip to main content

Table 2 Clinical parameters and laboratory results in the baseline and follow-up visits

From: The combined role of NT-proBNP and LV-GLS in the detection of early subtle chemotherapy-induced cardiotoxicity in breast cancer female patients

Variables

Baseline (mean± SD)

FU (mean± SD)

P value

SBP (mmHg)

118.9 ± 8.5

115.8 ± 7.5

0.001

DBP (mmHg)

71 ± 7.8

69.1 ± 8.1

0.084

HR (bpm)

81.4 ± 12.3

85.2 ± 13.7

0.012

Weight (kg)

72.4 ± 9.7

71.4 ± 9.4

0.117

BMI (kg/m2)

26.4 ± 2.7

26.2 ± 2.61

0.256

Hb (g/dl)

12.8 ±0.8

12.1 ± 1.1

<0.001

Platelets (× 109/L)

348.5 ± 98.9

333.3 ± 100.6

0.007

Creatinine (mg/dl)

0.8 ± 0.1

0.8 ± 0.1

0.779

NT-pro BNP, median (range), pg/ml

34.4 (446.2)

73.5 (956.4)

<0.001

Delta NT-pro BNP, median (range), pg/ml

16.2 (535.6)

  1. SBP systolic blood pressure, DBP diastolic blood pressure, BMI body mass index, HR heart rate, Hb hemoglobin